Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 575 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cytopenias Clear all
Terminated Phase 2 Interventional

Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes

NCT00104806
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
cholecalciferol, arsenic trioxide
Dietary Supplement · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 120 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 17, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Results available

Phase 1 Safety Study of Dimethyl Sulfoxide Cryopreserved Platelets

NCT02078284
View directory record Official record
Conditions
Thrombocytopenia
Interventions
CPP, LSP
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Lebanon, New Hampshire • Cincinnati, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 17, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

NCT00988715
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Cytopenia With Multilineage Dysplasia, Refractory Cytopenia With Multilineage Dysplasia and Ringed Sideroblasts, Secondary Acute Myeloid Leukemia
Interventions
Pretargeted Radioimmunotherapy, Cyclosporine, Mycophenolate Mofetil, Total-Body Irradiation, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Fludarabine Phosphate, Pharmacological Study, Laboratory Biomarker Analysis
Biological · Drug · Radiation + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 17, 2026, 4:08 AM EDT
Completed Phase 4 Interventional

Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin

NCT00039858
View directory record Official record
Conditions
Thrombocytopenia, Thrombosis
Interventions
Argatroban
Drug
Lead sponsor
Encysive Pharmaceuticals
Industry
Eligibility
Up to 16 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
13
States / cities
Los Angeles, California • Orange, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2007 · Synced Oct 17, 2026, 4:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.

NCT01933035
View directory record Official record
Conditions
Immune Thrombocytopenia, Chemotherapy Induced Thrombocytopenia, Myelodysplasia, Aplastic Anaemia
Interventions
Immune Thrombocytopenics, Hypo-proliferative thrombocytopenics, Control Population
Other
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 17, 2026, 4:08 AM EDT
Completed No phase listed Observational

Fatigue and Symptom Burden in Low-Risk Cancer Patients Undergoing Treatment for Febrile Neutropenia

NCT00503854
View directory record Official record
Conditions
Fatigue, Febrile Neutropenia, Solid Neoplasm
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Oct 17, 2026, 4:08 AM EDT
Terminated Phase 2 Interventional

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )

NCT04426201
View directory record Official record
Conditions
COVID-19, Lymphocytopenia
Interventions
CYT107, Placebo
Drug
Lead sponsor
Revimmune
Industry
Eligibility
25 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 17, 2026, 4:08 AM EDT
Withdrawn Phase 1 Interventional

Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia

NCT00886496
View directory record Official record
Conditions
Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Myelodysplastic Syndromes, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
recombinant human mannose-binding lectin
Biological
Lead sponsor
Enzon Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
3
States / cities
Orange, California • Washington D.C., District of Columbia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Oct 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)

NCT02643420
View directory record Official record
Conditions
Neutropenia, Breast Cancer
Interventions
SPI-2012, Pegfilgrastim, Docetaxel, Cyclophosphamide
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
76
States / cities
Glendale, Arizona • Tucson, Arizona • Yuma, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional

Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)

NCT00073580
View directory record Official record
Conditions
Thrombocytopenia, Thrombosis, Cardiac Disease, Coronary Artery Bypass Surgery
Interventions
Angiomax (bivalirudin) anticoagulant
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 17, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance

NCT05102370
View directory record Official record
Conditions
Clonal Cytopenia of Undetermined Significance, CCUS Clonal Cytopenia of Undetermined Significance
Interventions
Enasidenib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
12
States / cities
Rochester, Minnesota • St Louis, Missouri • Basking Ridge, New Jersey + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag

NCT00370331
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
eltrombopag, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
26
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional

Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients

NCT00220766
View directory record Official record
Conditions
Immunologic Deficiency Syndrome, Agammaglobulinemia, Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome, Common Variable Immunodeficiency
Interventions
Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified, Dextrose, 5% in Water
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
9
States / cities
Birmingham, Alabama • Denver, Colorado • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2009 · Synced Oct 17, 2026, 4:08 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease

NCT00962260
View directory record Official record
Conditions
Gaucher Disease
Interventions
Plant cell expressed recombinant glucocerebrosidase (prGCD)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
U.S. locations
14
States / cities
La Jolla, California • Aurora, Colorado • Coral Springs, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 17, 2026, 4:08 AM EDT
Completed No phase listed Observational

Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study

NCT05053100
View directory record Official record
Conditions
Acute Leukemia, Deep Vein Thrombosis, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Thrombocytopenia
Interventions
Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 17, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

NCT01151423
View directory record Official record
Conditions
Acquired Thrombotic Thrombocytopenic Purpura
Interventions
Caplacizumab, Placebo
Biological
Lead sponsor
Ablynx, a Sanofi company
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 17, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

NCT00054327
View directory record Official record
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
busulfan, cyclophosphamide, cytarabine, radiation therapy, Etoposide, Stem Cell Transfusion
Drug · Radiation · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Up to 55 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2013 · Synced Oct 17, 2026, 4:08 AM EDT
Terminated No phase listed Observational

A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone

NCT02050581
View directory record Official record
Conditions
Idiopathic Thrombocytopenia Purpura
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
3 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Oct 17, 2026, 4:08 AM EDT
Completed No phase listed Observational

Time From Onset of Fever to Administration of Antibiotics in Neutropenic Fever Patients

NCT03968328
View directory record Official record
Conditions
Febrile Neutropenia, Fever
Interventions
Interview, Survey Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 17, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Defibrotide TMA Prophylaxis Pilot Trial

NCT03384693
View directory record Official record
Conditions
Thrombotic Microangiopathies
Interventions
Defibrotide
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 30 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 17, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies

NCT00975819
View directory record Official record
Conditions
Kaposiform Hemangioendotheliomas, Tufted Angioma, Capillary Venous Lymphatic Malformation, Venous Lymphatic Malformation, Microcystic Lymphatic Malformation, Mucocutaneous Lymphangiomatosis and Thrombocytopenia, Capillary Lymphatic Arterial Venous Malformations, PTEN Overgrowth Syndrome With Vascular Anomaly, Lymphangiectasia Syndromes
Interventions
sirolimus
Drug
Lead sponsor
Denise Martin Adams
Other
Eligibility
Up to 31 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 17, 2026, 4:08 AM EDT
Terminated No phase listed Observational

Avatrombopag for the Treatment of Thrombocytopenia in Adults With Chronic Liver Disease Undergoing a Procedure

NCT03554759
View directory record Official record
Conditions
Thrombocytopenia
Interventions
Avatrombopag
Drug
Lead sponsor
Sobi, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Timeline
2018 – 2019
U.S. locations
41
States / cities
Chandler, Arizona • Lancaster, California • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 17, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)

NCT01822691
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
INCB024360
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 17, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate the Therapeutic Role of RNA Fragments in Platelet Production During Chemotherapy

NCT01163110
View directory record Official record
Conditions
Thrombocytopenia, Neoplasm, Cancer
Interventions
Realbuild
Dietary Supplement
Lead sponsor
Midwestern Regional Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Zion, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 15, 2013 · Synced Oct 17, 2026, 4:08 AM EDT